303 related articles for article (PubMed ID: 28364924)
1. Vaccine vial monitor availability and use in low- and middle-income countries: A systematic review.
Eriksson P; Gessner BD; Jaillard P; Morgan C; Le Gargasson JB
Vaccine; 2017 Apr; 35(17):2155-2161. PubMed ID: 28364924
[TBL] [Abstract][Full Text] [Related]
2. Costs of vaccine programs across 94 low- and middle-income countries.
Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
[TBL] [Abstract][Full Text] [Related]
3. Challenges to sustainable immunization systems in Gavi transitioning countries.
Cernuschi T; Gaglione S; Bozzani F
Vaccine; 2018 Oct; 36(45):6858-6866. PubMed ID: 30268735
[TBL] [Abstract][Full Text] [Related]
4. Gavi's Transition Policy: Moving From Development Assistance To Domestic Financing Of Immunization Programs.
Kallenberg J; Mok W; Newman R; Nguyen A; Ryckman T; Saxenian H; Wilson P
Health Aff (Millwood); 2016 Feb; 35(2):250-8. PubMed ID: 26858377
[TBL] [Abstract][Full Text] [Related]
5. Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.
Blau J; Hoestlandt C; D Clark A; Baxter L; Felix Garcia AG; Mounaud B; Mosina L
Vaccine; 2015 May; 33 Suppl 1():A34-9. PubMed ID: 25919171
[TBL] [Abstract][Full Text] [Related]
6. Applying lessons learned from the USAID family planning graduation experience to the GAVI graduation process.
Shen AK; Farrell MM; Vandenbroucke MF; Fox E; Pablos-Mendez A
Health Policy Plan; 2015 Jul; 30(6):687-95. PubMed ID: 24974106
[TBL] [Abstract][Full Text] [Related]
7. New vaccine adoption: qualitative study of national decision-making processes in seven low- and middle-income countries.
Burchett HE; Mounier-Jack S; Griffiths UK; Biellik R; Ongolo-Zogo P; Chavez E; Sarma H; Uddin J; Konate M; Kitaw Y; Molla M; Wakasiaka S; Gilson L; Mills A
Health Policy Plan; 2012 May; 27 Suppl 2():ii5-16. PubMed ID: 22513732
[TBL] [Abstract][Full Text] [Related]
8. Lessons learned in shaping vaccine markets in low-income countries: a review of the vaccine market segment supported by the GAVI Alliance.
Gilchrist SA; Nanni A
Health Policy Plan; 2013 Dec; 28(8):838-46. PubMed ID: 23174880
[TBL] [Abstract][Full Text] [Related]
9. Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries.
Saxenian H; Hecht R; Kaddar M; Schmitt S; Ryckman T; Cornejo S
Health Policy Plan; 2015 Mar; 30(2):197-205. PubMed ID: 24510369
[TBL] [Abstract][Full Text] [Related]
10. Country Ownership And Gavi Transition: Comprehensive Approaches To Supporting New Vaccine Introduction.
Shen AK; Weiss JM; Andrus JK; Pecenka C; Atherly D; Taylor K; McQuestion M
Health Aff (Millwood); 2016 Feb; 35(2):272-6. PubMed ID: 26858380
[TBL] [Abstract][Full Text] [Related]
11. Seizing market shaping opportunities for vaccine cold chain equipment.
Azimi T; Franzel L; Probst N
Vaccine; 2017 Apr; 35(17):2260-2264. PubMed ID: 28364940
[TBL] [Abstract][Full Text] [Related]
12. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
[TBL] [Abstract][Full Text] [Related]
13. Charting the evolution of approaches employed by the Global Alliance for Vaccines and Immunizations (GAVI) to address inequities in access to immunization: a systematic qualitative review of GAVI policies, strategies and resource allocation mechanisms through an equity lens (1999-2014).
Gandhi G
BMC Public Health; 2015 Nov; 15():1198. PubMed ID: 26621528
[TBL] [Abstract][Full Text] [Related]
14. Improving cold chain systems: Challenges and solutions.
Ashok A; Brison M; LeTallec Y
Vaccine; 2017 Apr; 35(17):2217-2223. PubMed ID: 27670076
[TBL] [Abstract][Full Text] [Related]
15. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
Brenzel L
Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
[TBL] [Abstract][Full Text] [Related]
16. Sustainability of National Immunization Programme (NIP) performance and financing following Global Alliance for Vaccines and Immunization (GAVI) support to the Democratic Republic of the Congo (DRC).
Le Gargasson JB; Breugelmans JG; Mibulumukini B; Da Silva A; Colombini A
Vaccine; 2013 Apr; 31(15):1886-91. PubMed ID: 23462529
[TBL] [Abstract][Full Text] [Related]
17. Post-GAVI sustainability of the Haemophilus influenzae type b vaccine program: The potential role of economic evaluation.
Le P; Nghiem VT; Swint JM
Hum Vaccin Immunother; 2016 Sep; 12(9):2403-5. PubMed ID: 27135964
[TBL] [Abstract][Full Text] [Related]
18. Effect of donor funding for immunization from Gavi and other development assistance channels on vaccine coverage: Evidence from 120 low and middle income recipient countries.
Ikilezi G; Augusto OJ; Dieleman JL; Sherr K; Lim SS
Vaccine; 2020 Jan; 38(3):588-596. PubMed ID: 31679863
[TBL] [Abstract][Full Text] [Related]
19. Strengthening legal frameworks for vaccination: The experiences of Armenia, Georgia, and Moldova.
Trumbo SP; Silver D; Domenti O; Gasoyan H; Paatashvili E; Gellin BG; Gordon JL
Vaccine; 2019 Aug; 37(35):4840-4847. PubMed ID: 30392764
[TBL] [Abstract][Full Text] [Related]
20. Shaping markets to benefit global health - A 15-year history and lessons learned from the pentavalent vaccine market.
Malhame M; Baker E; Gandhi G; Jones A; Kalpaxis P; Iqbal R; Momeni Y; Nguyen A
Vaccine X; 2019 Aug; 2():100033. PubMed ID: 31384748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
